Literature DB >> 23337454

[Characteristics of heroin dependent patients admitted to a methadone treatment program].

Arantza Sanvisens1, Inmaculada Rivas2, Eva Faure2, Trinidad Muñoz2, Manuela Rubio2, Daniel Fuster3, Jordi Tor1, Robert Muga4.   

Abstract

BACKGROUND AND OBJETIVE: Methadone is largely used as the primary opioid substitution therapy for the treatment of heroin addiction; the objective of the study was to describe the clinical characteristics of heroin abusers admitted into a methadone maintenance program (MMP) in metropolitan Barcelona.
METHOD: Cross-sectional study in patients enrolled in MMP since its introduction in 1992 through December 2010. Socio-demographic data, drug use characteristics, prevalence of blood-borne infections (human immunodeficiency virus [HIV], and hepatitis B [HBV] and C [HCV]) and psychiatric co-morbidity were assessed at entry.
RESULTS: One thousand and six hundred seventy eight patients (82.8% male). A total of 608 (36.2%) patients were admitted during 1992-1996, 566 (33.7%) between 1997-2001, 305 (18.2%) between 2002-2006 and 199 (11.9%) in the last period. Age at admission to methadone increased significantly (28 years in period 1992-1996 vs. 37 years in the last period [P<.005]). The percentage of patients with a history of intravenous drug use decreased significantly (89.5% in first period vs. 56.4% in period 2007-2010 [P<.05]). Prevalence of HIV, HCV and HBV (HBcAb+) was 53.7, 73.6 and 61.3%, respectively. The prevalence of HIV decreased over time from 66.2% in first period to 43.5% in 2007-2010 (P<.05); the prevalence of HCV decreased significantly from 82.8% in 1992-1996 to 69.8% in last period (P<.05). Twenty five percent of patients had psychiatric co-morbidity at admission and the prevalence of psychiatric co-morbidity increased over time (21% in 1992-1996 and 32% in 2007-2010; P<.05).
CONCLUSION: Age at first opioid substitution therapy is increasing over time, as well as the proportion of patients with psychiatric co-morbidity. There were significant reductions in blood-borne infections.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Keywords:  Addiction; Adicción; Co-morbidity; Comorbilidad; Heroin; Heroína; Metadona; Methadone

Mesh:

Substances:

Year:  2013        PMID: 23337454     DOI: 10.1016/j.medcli.2012.10.023

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  4 in total

1.  Sex stratification of the trends and risk of mortality among individuals living with HIV under different transmission categories.

Authors:  Chun-Yuan Lee; Yi-Pei Lin; Hung-Pin Tu; Sheng-Fan Wang; Po-Liang Lu
Journal:  Sci Rep       Date:  2022-06-03       Impact factor: 4.996

2.  Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study.

Authors:  Roberto Muga; Inmaculada Rivas; Eva Faure; Daniel Fuster; Paola Zuluaga; Manuela Rubio; Trinidad Muñoz; Marta Torrens; Jordi Tor; Arantza Sanvisens
Journal:  BMC Infect Dis       Date:  2014-09-17       Impact factor: 3.090

3.  Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study.

Authors:  Arantza Sanvisens; Inmaculada Rivas; Eva Faure; Néstor Espinach; Anna Hernandez-Rubio; Xavier Majó; Joan Colom; Robert Muga
Journal:  World J Gastroenterol       Date:  2020-10-14       Impact factor: 5.742

4.  HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019.

Authors:  Annemarie Rinder Stengaard; Lauren Combs; Virginie Supervie; Sara Croxford; Sarika Desai; Ann K Sullivan; Stine Finne Jakobsen; Quenia Santos; Daniel Simões; Jordi Casabona; Jeffrey V Lazarus; John B F de Wit; Frank M Amort; Anastasia Pharris; Lina Nerlander; Dorthe Raben
Journal:  Euro Surveill       Date:  2021-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.